93709-65-0

Basic information

• Product Name: 2-(4-METHOXY-BENZOYLAMINO)-3-METHYL-BUTYRIC ACID
• Synonyms: (4-Methoxybenzoyl)-l-valine;L-Valine, N-(4-methoxybenzoyl)-;2-[(4-Methoxyphenyl)formamido]-3-methylbutanoic Acid
• CAS NO: 93709-65-0
• Molecular Formula: C₁₃H₁₇NO₄
• Molecular Weight: 251.28
• Mol File: 93709-65-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 463.1°Cat760mmHg
• Flash Point: 233.8°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 2.26E-09mmHg at 25°C
• CAS DataBase Reference: 2-(4-METHOXY-BENZOYLAMINO)-3-METHYL-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-METHOXY-BENZOYLAMINO)-3-METHYL-BUTYRIC ACID(93709-65-0)
• EPA Substance Registry System: 2-(4-METHOXY-BENZOYLAMINO)-3-METHYL-BUTYRIC ACID(93709-65-0)

Safety Data

• Hazardous Substances Data: 93709-65-0(Hazardous Substances Data)

Usage

Structure

2-(4-Methoxy-benzoylamino)-3-methyl-butyric acid consists of a butyric acid derivative with a benzene ring, a methoxy group, and an amide functional group.

Type of compound

It is a chemical compound.

Potential pharmaceutical applications

The compound may have potential uses in drug design or as a building block in organic synthesis due to its structural features.

Importance in research

The properties and potential uses of 2-(4-Methoxy-benzoylamino)-3-methyl-butyric acid make it significant for further research and development in the fields of medicinal chemistry and pharmaceuticals.

InChI:InChI=1/C13H17NO4/c1-8(2)11(13(16)17)14-12(15)9-4-6-10(18-3)7-5-9/h4-8,11H,1-3H3,(H,14,15)(H,16,17)/p-1/t11-/m1/s1

Upstream product

• 100-07-2 4-methoxy-benzoyl chloride 
• 516-06-3 D,L-valine 
• 251538-67-7 C₁₄H₁₉NO₄ 
• 100-09-4 4-methoxybenzoic acid 
• 5619-05-6 DL-valine methyl ester hydrochloride 
• 696-62-8 para-iodoanisole 
• 18414-58-9 diphenylmethylsilanecarboxylic acid 
• 72-18-4 L-valine 

Downstream Products

• 79137-48-7 2-(4-methoxyphenyl)-5-oxo-4-iso-propyl-4,5-dihydrooxazole 
• 93709-96-7 4-MeOBz-D-Val-L-ValOMe 
• 93753-80-1 4-MeOBz-L-Val-L-ValOMe 
• 2108-54-5 1-(4-methoxyphenyl)pentane-1,4-dione 

Relevant articles and documents

A Novel N-Substituted Valine Derivative with Unique Peroxisome Proliferator-Activated Receptor γbinding Properties and Biological Activities

A proprietary library of novel N-Aryl-substituted amino acid derivatives bearing a hydroxamate head group allowed the identification of compound 3a that possesses weak proadipogenic and peroxisome proliferator-Activated receptor γ(PPARI) activating properties. The systematic optimization of 3a, in order to improve its PPARγagonist activity, led to the synthesis of compound 7j (N-Aryl-substituted valine derivative) that possesses dual PPARI/PPARα agonistic activity. Structural and kinetic analyses reveal that 7j occupies the typical ligand binding domain of the PPARγagonists with, however, a unique high-Affinity binding mode. Furthermore, 7j is highly effective in preventing cyclin-dependent kinase 5-mediated phosphorylation of PPARγserine 273. Although less proadipogenic than rosiglitazone, 7j significantly increases adipocyte insulin-stimulated glucose uptake and efficiently promotes white-To-brown adipocyte conversion. In addition, 7j prevents oleic acid-induced lipid accumulation in hepatoma cells. The unique biochemical properties and biological activities of compound 7j suggest that it would be a promising candidate for the development of compounds to reduce insulin resistance, obesity, and nonalcoholic fatty liver disease.

Catalytic Aerobic Cross-Dehydrogenative Coupling of Azlactones en Route to α,α-Disubstituted α-Amino Acids

We developed a catalytic aerobic method to synthesize α,α-disubstituted α-amino acids through cross-dehydrogenative coupling of azlactones. Combining an iron catalyst with a bisoxazolidine ligand resulted in high catalytic performance, and cross-coupling with an indole proceeded smoothly under aerobic conditions. A wide variety of α-aryl and aliphatic amino acid derived azlactones were applied to the present catalysis. In addition, a quaternary carbon could be constructed using oxindole and benzofuranone under aerobic conditions.

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISTS, METHOD OF PREPARATION AND USES THEREOF

The present invention relates to new peroxisome proliferator-activated receptor gamma (PPAR?) agonists, and their uses as in the prevention and/or treatment of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hyperlipidemia and hypertriglyceridemia. The preparation said compounds is also described.